12/20
04:34 pm
lxrx
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) [Yahoo! Finance]
Low
Report
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) [Yahoo! Finance]
12/20
04:30 pm
lxrx
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
Medium
Report
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
11/27
08:01 am
lxrx
Lexicon completes subject enrolment for DPNP trial of LX9211 [Yahoo! Finance]
Low
Report
Lexicon completes subject enrolment for DPNP trial of LX9211 [Yahoo! Finance]
11/26
08:06 am
lxrx
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) [Yahoo! Finance]
Low
Report
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) [Yahoo! Finance]
11/26
08:00 am
lxrx
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Low
Report
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
11/25
04:21 pm
lxrx
Lexicon Pharmaceuticals to Participate in December Investor Conferences [Yahoo! Finance]
Low
Report
Lexicon Pharmaceuticals to Participate in December Investor Conferences [Yahoo! Finance]
11/25
04:15 pm
lxrx
Lexicon Pharmaceuticals to Participate in December Investor Conferences
Low
Report
Lexicon Pharmaceuticals to Participate in December Investor Conferences
11/22
01:13 pm
lxrx
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Low
Report
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
11/22
07:39 am
lxrx
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA [Yahoo! Finance]
High
Report
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA [Yahoo! Finance]
11/22
07:32 am
lxrx
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
High
Report
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
11/20
04:15 pm
lxrx
Lexicon Appoints Ivan H. Cheung to Board of Directors [Yahoo! Finance]
Medium
Report
Lexicon Appoints Ivan H. Cheung to Board of Directors [Yahoo! Finance]
11/20
04:05 pm
lxrx
Lexicon Appoints Ivan H. Cheung to Board of Directors
Medium
Report
Lexicon Appoints Ivan H. Cheung to Board of Directors
11/18
08:35 am
lxrx
Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week [Yahoo! Finance]
Medium
Report
Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week [Yahoo! Finance]
11/14
08:12 am
lxrx
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago [Yahoo! Finance]
Low
Report
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago [Yahoo! Finance]
11/14
08:00 am
lxrx
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago
Low
Report
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago
11/13
08:06 am
lxrx
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Medium
Report
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
11/13
08:05 am
lxrx
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
11/13
02:32 am
lxrx
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... [Yahoo! Finance]
Medium
Report
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... [Yahoo! Finance]
11/12
04:12 pm
lxrx
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
11/12
04:05 pm
lxrx
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
11/11
07:33 am
lxrx
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look For [Yahoo! Finance]
Neutral
Report
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look For [Yahoo! Finance]
11/6
08:28 pm
lxrx
Qiagen (QGEN) Q3 Earnings and Revenues Top Estimates [Yahoo! Finance]
Medium
Report
Qiagen (QGEN) Q3 Earnings and Revenues Top Estimates [Yahoo! Finance]
11/6
08:00 am
lxrx
Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference
Medium
Report
Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference
11/5
04:05 pm
lxrx
Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease
Medium
Report
Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease
11/5
09:48 am
lxrx
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.